Welcome
Support Centre
30 July 2010 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A Multicentre, Multinational, Double Blind, Randomised, Parallel Group, Placebo-Controlled Study of Ethyl-Eicosapentaenoate (EPA) in Patients with Huntington's Disease (HD)
Source of recordUK Trials
ISRCTNISRCTN79170611
Date ISRCTN assigned03/02/2003
Local reference number(s)LA01.01.0005
Public titleA Multicentre, Multinational, Double Blind, Randomised, Parallel Group, Placebo-Controlled Study of Ethyl-Eicosapentaenoate (EPA) in Patients with Huntington's Disease (HD)
Scientific title
AcronymN/A
Disease/condition/study domainHuntington's disease
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Written informed consent
2. Availability of a responsible family member or carer to look after the patient during the trial and ensure complete compliance
3. Diagnosis of HD in stage I
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Status of trialCompleted
Target number of participantsNot provided at time of registration
InterventionsTwo groups randomly allocated to placebo or 2 g/day ethyl EPA on a double blind basis.

Patients who completed the 12 month randomisation phase of the trial were invited to take part in a further 12 month open label phase receiving 2 g/day Ethyl EPA.
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingLaxdale Ltd
Sponsor nameLaxdale Ltd
Sponsor detailsKings Park House
Laurelhill Business Park
Polmaise Road
Stirling
United Kingdom
FK7 9JQ
Sponsor telephone+44 (0)1786 476001
Sponsor fax+44 (0)1786 473137
Sponsor emailadmin@Laxdale.co.uk
Contact nameDr Harald Murck
Contact detailsLaxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
Stirling
United Kingdom
FK7 9JQ
Contact telephone+44 (0) 1786 476001
Contact fax+44 (0) 1786 473137
Contact emailhmurck@laxdale.co.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN79170611
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central